Hypermarcas (OTCMKTS:HYPMY - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $4.78, but opened at $5.00. Hypermarcas shares last traded at $5.00, with a volume of 2,980 shares trading hands.
Analyst Ratings Changes
Separately, Scotiabank raised shares of Hypermarcas to a "strong-buy" rating in a report on Thursday.
Get Our Latest Analysis on HYPMY
Hypermarcas Trading Up 4.0%
The company has a 50 day moving average price of $4.66 and a two-hundred day moving average price of $3.82. The firm has a market capitalization of $3.06 billion, a price-to-earnings ratio of 20.10 and a beta of 0.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26.
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The company reported ($0.04) earnings per share for the quarter. The firm had revenue of $184.34 million for the quarter. Hypermarcas had a net margin of 12.51% and a return on equity of 6.95%.
Hypermarcas Dividend Announcement
The business also recently disclosed a dividend, which will be paid on Friday, January 8th. Shareholders of record on Tuesday, July 1st will be paid a $0.0345 dividend. The ex-dividend date is Monday, June 30th. This represents a yield of 2.81%. Hypermarcas's dividend payout ratio is presently 58.33%.
About Hypermarcas
(
Get Free Report)
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Featured Articles
Before you consider Hypermarcas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.
While Hypermarcas currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
